AI assistant
GENELUX Corp — Director's Dealing 2025
Sep 3, 2025
33857_dirs_2025-09-03_a4bf6227-498f-4924-ae7e-3858d773ef55.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: GENELUX Corp (GNLX)
CIK: 0001231457
Period of Report: 2025-09-01
Reporting Person: Yu Yong (SVP, Clinical Development)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-09-01 | Stock Option (Right to Buy) | $6.00 | D | 207652 | Disposed | 2029-09-20 | Common stock (207652) | Direct |
| 2025-09-01 | Stock Option (Right to Buy) | $3.33 | A | 207652 | Acquired | 2029-09-20 | Common stock (207652) | Direct |
| 2025-09-01 | Stock Option (Right to Buy) | $22.40 | D | 65000 | Disposed | 2033-09-10 | Common stock (65000) | Direct |
| 2025-09-01 | Stock Option (Right to Buy) | $3.33 | A | 65000 | Acquired | 2033-09-10 | Common stock (65000) | Direct |
Footnotes
F1: The shares subject to the option are fully vested.
F2: The transactions reported herein reflect a one-time reduction of the exercise prices of these stock options, effective September 1, 2025, to an exercise price of $3.33 per share, the price of the Issuer's common stock on September 1, 2025. There is no change to the expiration dates or the vesting schedule of the stock options.
F3: The shares subject to the option vest as follows: 25% on September 11, 2024, and the remaining shares vest in 36 equal monthly installments thereafter.